Jesper Kjerulff leads again
PharmNovo is very pleased to inform you that our former project leader, Jesper Kjerulff has returned as project leader and Chief Operations Officer.
Jesper has extensive knowledge and experience of working strategically and successfully with the drug development process from preclinical through phase I,II and III, on to registration and launch. Jesper has an intimate knowledge of the PN6047 project from his former role, and it will be a privilege for all of us at PharmNovo to have Jesper back in the team continuing the journey with PN6047.
Jesper Kjerulff leads again
PharmNovo is very pleased to inform you that our former project leader, Jesper Kjerulff has returned as project leader and Chief Operations Officer.
Jesper has extensive knowledge and experience of working strategically and successfully with the drug development process from preclinical through phase I,II and III, on to registration and launch. Jesper has an intimate knowledge of the PN6047 project from his former role, and it will be a privilege for all of us at PharmNovo to have Jesper back in the team continuing the journey with PN6047.
Latest news
View all
Positive final Phase I results
The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.
Read more
Visionaries in pain relief: PharmNovo presents Bengt von Mentzer, founder and Chief scientific advisor.
Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.
Read more
NIDA funds studies
The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.
Read more
Meet Olof Breuer, MD, Clinical pharmacology lead
Olof Breuer's presence at PharmNovo exemplifies the company's commitment to pioneering advancements in pain relief. His visionary approach, honed through years of experience, positions him as a driving force in the quest for novel concepts in neuropathic pain relief.
Read more